The clinical perspectives of CDX2 expression in colorectal cancer

A qualitative systematic review

Jesper Olsen, Maiken Lise Marcker Espersen, P Jess, LT Kirkeby, Jesper Thorvald Troelsen

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

    Resumé

    Homeobox genes are often deregulated in cancer. They can have both oncogenic and tumor-suppressing potential. The Caudal-related homeobox transcription factor 2 (CDX2) is an intestine-specific transcription factor. It is implicated in differentiation, proliferation, cell-adhesion, and migration. CDX2 has been proposed as a tumor suppressor in colorectal cancer but its role is still controversial. This systematic review were undertaken in order to clarify CDX2s role in colorectal cancer.
    METHODS:
    A literature search was performed in the MEDLINE database from 1966 to February 2014. Only studies in which all or a part of the experimental design were performed on human colorectal cancer tissue were included. Thus, studies solely performed in cell-lines or animal models were excluded.
    RESULTS:
    Fifty-two articles of relevance were identified. CDX2 expression was rarely lost in colorectal cancers, however the expression pattern may often be heterogeneous within the tumor and can be selectively down regulated at the invasive front and in tumor buddings. Loss of CDX2 expression is probably correlated to tumor grade, stage, right-sided tumor location, MMR-deficiency, CIMP, and BRAF mutations. The CDX2 gene is rarely mutated but the locus harboring the gene is often amplified and may suggest CDX2 as a linage-survival oncogene. CDX2 might be implicated in cell proliferation and migration through cross-talk with the Wnt-signaling pathway, tumor-stroma proteins, and inflammatory cytokines.
    CONCLUSION:
    A clear role for CDX2 expression in colorectal cancer remains to be elucidated, and it might differ in relation to the underlying molecular pathways leading to the cancer formation
    OriginalsprogEngelsk
    TidsskriftSurgical Oncology
    Vol/bind23
    Udgave nummer3
    Sider (fra-til)167-176
    ISSN0960-7404
    DOI
    StatusUdgivet - 2014

    Citer dette

    Olsen, Jesper ; Espersen, Maiken Lise Marcker ; Jess, P ; Kirkeby, LT ; Troelsen, Jesper Thorvald. / The clinical perspectives of CDX2 expression in colorectal cancer : A qualitative systematic review. I: Surgical Oncology. 2014 ; Bind 23, Nr. 3. s. 167-176.
    @article{d3a9ad169d0d489cbfbab51686cac491,
    title = "The clinical perspectives of CDX2 expression in colorectal cancer: A qualitative systematic review",
    abstract = "Homeobox genes are often deregulated in cancer. They can have both oncogenic and tumor-suppressing potential. The Caudal-related homeobox transcription factor 2 (CDX2) is an intestine-specific transcription factor. It is implicated in differentiation, proliferation, cell-adhesion, and migration. CDX2 has been proposed as a tumor suppressor in colorectal cancer but its role is still controversial. This systematic review were undertaken in order to clarify CDX2s role in colorectal cancer.METHODS:A literature search was performed in the MEDLINE database from 1966 to February 2014. Only studies in which all or a part of the experimental design were performed on human colorectal cancer tissue were included. Thus, studies solely performed in cell-lines or animal models were excluded.RESULTS:Fifty-two articles of relevance were identified. CDX2 expression was rarely lost in colorectal cancers, however the expression pattern may often be heterogeneous within the tumor and can be selectively down regulated at the invasive front and in tumor buddings. Loss of CDX2 expression is probably correlated to tumor grade, stage, right-sided tumor location, MMR-deficiency, CIMP, and BRAF mutations. The CDX2 gene is rarely mutated but the locus harboring the gene is often amplified and may suggest CDX2 as a linage-survival oncogene. CDX2 might be implicated in cell proliferation and migration through cross-talk with the Wnt-signaling pathway, tumor-stroma proteins, and inflammatory cytokines.CONCLUSION:A clear role for CDX2 expression in colorectal cancer remains to be elucidated, and it might differ in relation to the underlying molecular pathways leading to the cancer formation.",
    author = "Jesper Olsen and Espersen, {Maiken Lise Marcker} and P Jess and LT Kirkeby and Troelsen, {Jesper Thorvald}",
    year = "2014",
    doi = "10.1016/j.suronc.2014.07.003",
    language = "English",
    volume = "23",
    pages = "167--176",
    journal = "Surgical Oncology",
    issn = "0960-7404",
    publisher = "Elsevier Ltd",
    number = "3",

    }

    The clinical perspectives of CDX2 expression in colorectal cancer : A qualitative systematic review. / Olsen, Jesper; Espersen, Maiken Lise Marcker; Jess, P; Kirkeby, LT; Troelsen, Jesper Thorvald.

    I: Surgical Oncology, Bind 23, Nr. 3, 2014, s. 167-176.

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

    TY - JOUR

    T1 - The clinical perspectives of CDX2 expression in colorectal cancer

    T2 - A qualitative systematic review

    AU - Olsen, Jesper

    AU - Espersen, Maiken Lise Marcker

    AU - Jess, P

    AU - Kirkeby, LT

    AU - Troelsen, Jesper Thorvald

    PY - 2014

    Y1 - 2014

    N2 - Homeobox genes are often deregulated in cancer. They can have both oncogenic and tumor-suppressing potential. The Caudal-related homeobox transcription factor 2 (CDX2) is an intestine-specific transcription factor. It is implicated in differentiation, proliferation, cell-adhesion, and migration. CDX2 has been proposed as a tumor suppressor in colorectal cancer but its role is still controversial. This systematic review were undertaken in order to clarify CDX2s role in colorectal cancer.METHODS:A literature search was performed in the MEDLINE database from 1966 to February 2014. Only studies in which all or a part of the experimental design were performed on human colorectal cancer tissue were included. Thus, studies solely performed in cell-lines or animal models were excluded.RESULTS:Fifty-two articles of relevance were identified. CDX2 expression was rarely lost in colorectal cancers, however the expression pattern may often be heterogeneous within the tumor and can be selectively down regulated at the invasive front and in tumor buddings. Loss of CDX2 expression is probably correlated to tumor grade, stage, right-sided tumor location, MMR-deficiency, CIMP, and BRAF mutations. The CDX2 gene is rarely mutated but the locus harboring the gene is often amplified and may suggest CDX2 as a linage-survival oncogene. CDX2 might be implicated in cell proliferation and migration through cross-talk with the Wnt-signaling pathway, tumor-stroma proteins, and inflammatory cytokines.CONCLUSION:A clear role for CDX2 expression in colorectal cancer remains to be elucidated, and it might differ in relation to the underlying molecular pathways leading to the cancer formation.

    AB - Homeobox genes are often deregulated in cancer. They can have both oncogenic and tumor-suppressing potential. The Caudal-related homeobox transcription factor 2 (CDX2) is an intestine-specific transcription factor. It is implicated in differentiation, proliferation, cell-adhesion, and migration. CDX2 has been proposed as a tumor suppressor in colorectal cancer but its role is still controversial. This systematic review were undertaken in order to clarify CDX2s role in colorectal cancer.METHODS:A literature search was performed in the MEDLINE database from 1966 to February 2014. Only studies in which all or a part of the experimental design were performed on human colorectal cancer tissue were included. Thus, studies solely performed in cell-lines or animal models were excluded.RESULTS:Fifty-two articles of relevance were identified. CDX2 expression was rarely lost in colorectal cancers, however the expression pattern may often be heterogeneous within the tumor and can be selectively down regulated at the invasive front and in tumor buddings. Loss of CDX2 expression is probably correlated to tumor grade, stage, right-sided tumor location, MMR-deficiency, CIMP, and BRAF mutations. The CDX2 gene is rarely mutated but the locus harboring the gene is often amplified and may suggest CDX2 as a linage-survival oncogene. CDX2 might be implicated in cell proliferation and migration through cross-talk with the Wnt-signaling pathway, tumor-stroma proteins, and inflammatory cytokines.CONCLUSION:A clear role for CDX2 expression in colorectal cancer remains to be elucidated, and it might differ in relation to the underlying molecular pathways leading to the cancer formation.

    U2 - 10.1016/j.suronc.2014.07.003

    DO - 10.1016/j.suronc.2014.07.003

    M3 - Review

    VL - 23

    SP - 167

    EP - 176

    JO - Surgical Oncology

    JF - Surgical Oncology

    SN - 0960-7404

    IS - 3

    ER -